ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LXEO
CABA (33) LCTX (20) IPSC (18) FATE (35) ⌘ Pro Terminal →

Lexeo Therapeutics Inc. (LXEO) — RQD Stock Rating Cockpit

$3.06 -2.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.04

Lexeo Therapeutics Inc. (LXEO) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $257.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LXEO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LXEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lexeo Therapeutics Inc. (NASDAQ: LXEO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.06 (-2.55% 1D, market cap $257.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LXEO ranks #681 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LXEO compare to CABA and LCTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LXEO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, LXEO leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LXEO?
▼

Per LXEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907108), Lexeo Therapeutics Inc. generated $305.9M in revenue (+3.3% YoY), -$100.0M in net income, and -$99.0M in free cash flow against $268.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.04 (-0.65%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (5)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
$12 Bull$3 Base$2 Bear
📬 FREE LXEO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LXEO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY LXEO SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (21% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 48.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
25
Grade E$2.74+10.2% Next Q
Q2 (-2Q)
28
Grade E$3.02-5% Next Q
Q3 (-1Q)
30
Grade E$2.87+6.6% Next Q
Current
33
Grade E$3.06-8.9% Hist 90D α
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LXEO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LXEO currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.68) and Max Pain ($3.21) forces dealer call-delta covering toward $11.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LXEO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LXEO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $3$3.06H: $11
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LXEO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (28)

10/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like LXEO
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXEO)

  • ✓Walkthrough of LXEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LXEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.24%▼ DESCENDING CHANNEL
2026-11-03O $3.06H $3.14L $3.06C $3.06VOL 1.00M
RES: $4.63SUP: $2.37SMA50: $3.68SMA200: $5.17
$7.48$6.15$4.81$3.47$2.14RES $4.63SUP $2.37$3.062026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LXEO Butterfly Map → + Track LXEO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LXEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LXEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LXEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXEO)

Health Care Rank #681 of 1016 ⚔️ CABA vs LXEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LXEO vs. CABA, LCTX, IPSC, FATE)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexeo Therapeutics Inc. (LXEO) ranks #681 by composite RQD confidence (33/100, grade E) and #534 by equity capitalization ($257.6M). Within this direct 5-issuer industry benchmark cohort, LXEO leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with LXEO at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LXEO ACTIVE
Lexeo Therapeutics Inc.
E 33/100 — — -35.0% -2.55% $257.6M Benchmark Subject
CABA
Cabaletta Bio Inc.
E 33/100 — — -35.0% -5.30% $256.0M /caba-vs-lxeo →
LCTX
Lineage Cell Therapeutics Inc.
E 20/100 — — -35.0% +1.00% $252.9M /lctx-vs-lxeo →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.68% $266.2M /ipsc-vs-lxeo →
FATE
Fate Therapeutics Inc.
D- 35/100 — — -35.0% -3.36% $249.2M /fate-vs-lxeo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907108

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexeo Therapeutics Inc. (LXEO) reported GAAP revenue of $305.9M (+3.3% vs. FY2024 revenue of $296.1M , and +59.5% cumulative change since FY2023) , GAAP net income of -$100.0M, operating cash flow of -$98.6M, and free cash flow of -$99.0M (-21.2% YoY). On the balance sheet, LXEO closed FY2025 with $268.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $305.9M -$100.0M -$98.6M -$99.0M $268.7M —
FY2024 (FY) 2024-12-31 $296.1M -$98.3M -$81.2M -$81.6M $146.9M —
FY2023 (FY) 2023-12-31 $191.8M -$66.4M -$59.5M -$59.5M — —

3. LXEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lexeo Therapeutics Inc. (NASDAQ: LXEO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.06 (-2.55% 1D, market cap $257.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LXEO ranks #681 in composite RQD confidence.

How does LXEO compare to CABA and LCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LXEO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, LXEO leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LXEO?

Per LXEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907108), Lexeo Therapeutics Inc. generated $305.9M in revenue (+3.3% YoY), -$100.0M in net income, and -$99.0M in free cash flow against $268.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LXEO trading relative to its 50-day, 200-day, and 52-week technical levels?

LXEO last traded at $3.06 (-2.55% on volume of 1,220,459 shares), positioning the stock -16.85% below its 50-day simple moving average ($3.68) and -40.81% below its 200-day simple moving average ($5.17). Across its 52-week range of $2.55 to $10.99, LXEO sits at the 6.0% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.68 to $3.44).

Direct Sub-Reports: LXEO RQD Cockpit LXEO 12M Forecast LXEO Earnings & Move LXEO Dividends & DRIP LXEO Insiders & 13F LXEO Whale Options LXEO Profit Sankey LXEO News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

LXEO — Lexeo Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lexeo Therapeutics Inc. (LXEO) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.06 (-2.55% 1D, market capitalization $257.6M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lexeo Therapeutics Inc. (LXEO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. The profile reports a market capitalization of $0.3B. —: customer base, product or revenue model, and how the company monetizes its activities. Reported revenue is — in each of the periods shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lexeo Therapeutics Inc. (LXEO) reported $305.9M in annual revenue (up from $296.1M in FY2024, +3.3% YoY) and -$100.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($191.8M revenue, -$66.4M net income) through FY2025, LXEO scaled operating cash flow to -$98.6M and free cash flow to -$99.0M, backed by $268.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.55 – $10.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

—: upstream suppliers, downstream customers, and sector correlation data. Investors should watch for the institutional accumulation signal in the news feed, the PKP2-ACM clinical discussion items, and the 52-week price range of $2.55 to $10.

  • Key Question #1: Can LXEO sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $305.9M and free cash flow of -$99.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LXEO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LXEO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lexeo Therapeutics Inc. (LXEO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LXEO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LXEO Bull vs. Bear Conversation Board — What's Your Call at $3.06?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LXEO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LXEO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $3.80 (+21.0%)
📌 Pinned Debate

The balance-sheet pillar scores 10 out of 20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash rose to $63.0M in

The balance-sheet pillar scores 10 out of 20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash rose to $63.0M in FY 2025.. When you look under the hood at LXEO, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $10.99. My 12M target is $3.80.

VolSurface_Trader 🐂 BULL

Both sides have a point here — LXEO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $2.57 (-18.2%)
Spot @ $3.14

With ROIC at -35%, FCF of -$99.0M in FY 2025, zero reported revenue, and a Piotroski F-Score of 2/9, the company generates no evident c

Fading this rally in LXEO at $3.14. With ROIC at -35%, FCF of -$99.0M in FY 2025, zero reported revenue, and a Piotroski F-Score of 2/9, the company generates no evident cash return on its operations.. With a beta of 1.0 and the stock sitting at $3.14 (52-wk range $2.55–$10.99), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%